Aim: Her2 amplification is present in a subgroup of gastroesophageal cancers (GCs). Her2 inhibition with Trastuzumab has shown to improve clinical outcomes in metastatic disease. Lapatinib ditosylate (LAP), a dual anti EGFR and anti Her2 tyrosine kinase inhibitor with preclinical activity against GC, has been approved in Her2 positive breast cancer. We aimed to study the activity of LAP in HER2 amplified GC. Methods: Patients ( pts) with Her2 positive (FISH ratio ≥2.0 or IHC3+ if ratio was between 1.8 and <2.0) advanced GC were randomly allocated 1:1 to receive LAP 1250 mg per day 1-21 plus capecitabine (CAP) 2000mg/m 2 on days 1-14 of a 21-day cycle or LAP 1500 mg monotherapy day 1-21 after having failed on a platinum-based first-line therapy. Her2 status was assessed centrally. The primary endpoint was the objective response rate (complete or partial response) as assessed by the investigator using RECIST 1.1 criteria. We aimed to include 38 pts per arm to show an interesting response rate of >20% in either of the two arms. Results: 37 pts were enrolled (18 to LAP + CAP, 19 to LAP mono). Pts received a median of three treatment cycles. 10 pts in the LAP + CAP group (56%) and 7 pts in the LAP mono group (37%) had received prior Trastuzumab. Only two pts (11.1%; 95% CI: 1.37 -34.7), both in the LAP + CAP arm, achieved an objective response. Therefore, the study was closed prematurely. 
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